The company

Eurocine Vaccines has attracted internationally recognized experts to quest for the vaccines of tomorrow. Specialized in vaccine development, and with decades long experience, the highly qualified team has a proven record to manage all aspects of vaccine development including preclinical and clinical development, scalability into production, as well as business development and financing.

Today a publicly listed company situated close to the Karolinska Institutet, home of the Nobel Assembly, using its clinically validated technology Endocine™ to develop new vaccines.​



President, CEO and Board Director

Dr. Hans Arwidsson

Dr. Hans Arwidsson, President, CEO and Board Director, is an executive with broad cross-functional experience from the pharmaceutical industry, e.g. Astra and AstraZeneca. Arwidsson holds a M.Sc. and a Ph.D. in pharmaceutical sciences from Uppsala University as well as an Executive MBA from Stockholm School of Economics.

Director of CMC Development

Ms. Sandra Jeldes Granstrand

Sandra Jeldes Granstrand, Director of CMC Development, Chemistry Manufacturing and Control, graduated as Master of Engineering, specialized in Bio-Medical Technology. Previously Deputy Head of Laboratory and CMC at Newron.

Director of Preclinical Development

Dr. Karl Ljungberg

Dr. Karl Ljungberg has an extensive experience of immunology, virology and particularly vaccinology from Karolinska Institutet, University of North Carolina and Public Health Agency of Sweden. Dr. Ljungberg holds a M.Sc. in Molecular Biology from Stockholm University and a Ph.D. in Infectious Disease Control from Karolinska Institutet.


Chairman of the Board

Dr. Pierre A. Morgon

Pierre A. Morgon holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He has previously served at senior positions at e.g. ICI-Pharma, Synthelabo, Aventis Sanofi Pasteur, Yamanouchi Pharma, BMS, Drug Abuse Sciences, Schering-Plough and Bio Alliance Pharma. Today he is CEO of MRGN Advisors, Chairman of Virometix and Theradiag, Board Member of Vaccitech and Univercells, as well as Regional Partner of Merieux Develeppement.

Non-Executive Director of the Board

Mr. Jan Sandström​

Jan Sandström, Master of Pharmaceutical Sciences, has both an extensive experience from the pharmaceutical industry as Business Developer and Board Member including Astrazeneca, PledPharma and TikoMed.

Non-Executive Director of the Board

Mr. Pär Thuresson

Pär Thuresson is president and CEO of an Industry Group and is also serving as a non-executive Director in several other companies.

President, CEO and Board Director

Dr. Hans Arwidsson

Please see Management above.

Stakeholders & Governance

Eurocine Vaccines (EUCI) is listed at Spotlight Stock Market. Among the major shareholders you may find board members, partners and employees along with over 4 000 other shareholders.

Legal advisor is Advokatfirman Lindahl.

Next financial report, July 2019 – March 2020, will be released May 27th 2020

List of Shareholders

Do you want to follow Eurocine Vaccines development?

Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.

Start your subscription here »